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Abstract
Objective: To analyse how testing the population influences the health indicators used to monitor the COVID-19 pandemic 
in the 50 countries with the highest number of diagnosed cases. Methods: This was an ecological study using secondary data 
retrieved on 8/19/2020. Cumulative incidence, mortality rate, case-fatality rate, and proportion of positive tests were calculated. 
The data were described and presented graphically, with their respective Spearman Correlation Coefficients. Results: The 
testing rate varied enormously between countries. Cumulative incidence and the proportion of positive tests were correlated 
with the number of tests, while the mortality rate and case-fatality rate showed low correlation with this indicator. Conclusion: 
Most countries do not test enough to ensure adequate monitoring of the pandemic, and this is reflected in the quality of the 
indicators. Expanding the number of tests is essential, but it needs to be accompanied by other measures, such as isolation of 
diagnosed cases and contact tracing.
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Introduction
Between the first case of the novel coronavirus 
disease (COVID-19) being identified and August 19, 
2020, more than 22 million cases were diagnosed, and 
781,000 deaths were reported worldwide.1
with severe symptoms, those who have had contact 
with a confirmed case and those belonging to ‘high-
risk’ groups; or to a combination of these and other 
criteria.6 This has happened in the European countries 
most affected by the epidemic, in the United States and 
Japan, and in low and middle-income Asian, African 
and Latin American countries.
The testing strategies adopted influence the 
estimated number of SARS-CoV-2 infections and 
deaths. Therefore, the strategies adopted affect the 
quality of health indicators that are essential for 
planning and executing actions aimed at controlling 
the pandemic.2,7
This article aimed to analyze how population 
testing influences the health indicators used to 
monitor the COVID-19 pandemic in the 50 countries 
with the highest number of diagnosed cases.
Methods
This survey consists of an ecological study 
performed on secondary data. The 50 countries with 
the highest number of COVID-19 diagnosed cases 
were selected, reported as at August 19, 2020, the date 
on which the data were retrieved. Testing data were 
obtained from the Worldometers website (https://
www.worldometers.info/coronavirus/). 
Worldometers is a website that analyzes, validates 
and aggregates data from thousands of real-time 
sources, including official websites of ministries of 
health and/or other government bodies, social media 
accounts of government officials and, eventually, 
information from important and reliable news 
channels, whose data is available before being 
published on official websites. In Worldometers, the 
information available does not distinguish between 
the type of test performed (RT-PCR or serologic), 
which is why in this document, when referring to 
testing for SARS-CoV-2, both RT-PCR and serologic 
tests are addressed. 
COVID-19 cases and deaths were obtained from 
the European Center for Disease Control website.1 
The case definition varies from country to country: 
some consider ‘confirmed cases’ to be only those with 
laboratory diagnosis, while others consider ‘COVID-19 
cases’ to be both those with laboratory diagnosis and 
those identified by clinical-epidemiological criteria. 
This document considers ‘diagnosed COVID-19 cases’, 
The high spreading power of the coronavirus 
causing the disease, SARS-CoV-2, and the growing 
number of cases reinforce the importance of 
understanding the epidemiological situation in 
a country or region in order to plan the most 
appropriate responses.2 Accordingly, laboratory 
testing to diagnose infection is of paramount 
importance to ascertain the infection’s magnitude, 
control and monitoring. 
Testing can be used to (i) identify the active 
presence of the virus by detecting its genome in 
upper and lower respiratory tract samples, with the 
real-time reverse transcription polymerase chain 
reaction (real-time RT-PCR) test being the most 
adopted; testing also allows (ii) detection of specific 
antibodies in blood samples, the presence of which 
is indicative of previous infection, the latter being 
serologic tests, functionally simpler and frequently 
used in epidemiological surveys.3
Despite the importance testing has for controlling 
SARS-CoV-2 infection, the strategies employed vary 
among different countries and epidemic stages.4 
Asian countries already affected by other respiratory 
epidemics, such as Taiwan and Hong Kong (China), 
and others, such as New Zealand, Iceland, Monaco, 
and Germany, have adopted broader strategies, usually 
testing suspects with mild symptoms to identify and 
isolate cases and track their respective contacts.5
Other countries, due to budget constraints, 
population size or the plans of the current government, 
have adopted more limited strategies.5 In such 
circumstances, testing has been restricted to people 
The testing strategies adopted influence 
the quality of health indicators that are 
essential for planning and executing 
actions aimed at controlling the 
pandemic.
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regardless of the diagnostic criteria used. In turn, the 
2019 population estimates were obtained from the 
World Bank (https://data.worldbank.org/indicator/
SP.POP.TOTL).
Based on these data, the following indicators were 
calculated: 
a) testing rate (number of tests performed, per one 
million inhabitants);
b) cumulative incidence (number of diagnosed cases 
divided by local population, presented per one 
million inhabitants);
c) mortality rate (number of deaths from the disease 
divided by the local population, presented per one 
million inhabitants);
d) case fatality rate (number of deaths per number of 
registered cases, expressed as a percentage); and
e) proportion of positive tests (number of positive 
tests per number of tests performed, expressed as 
a percentage).
Descriptive analyses and graphical representations 
(scatter diagrams) of cumulative incidence, mortality 
rate, fatality rate and proportion of positive tests in 
relation to each country’s testing rate were performed. 
For each scatter plot, a linear line representing the 
expected values of the indicator analyzed for the test 
rate is estimated. A 95% confidence interval (95% CI) is 
superimposed on this straight line and shown in gray. 
The linear or logarithmic scale used in the graphs was 
selected to permit a more accurate view of the trends. 
The data did not show normal distribution 
(Shapiro-Wilk: p-value<0.001), which is why 
Spearman’s correlation coefficient was used to 
evaluate the correlations between the number of 
tests and the selected health indicators (cumulative 
incidence, mortality rate, fatality rate and proportion 
of positive tests). The data were processed and analyzed 
by the ggplot28 statistical package in R version 4.0.1.9
Results
Figure 1 shows how many tests were performed per 
one million inhabitants. A first group of countries that 
performed more than 100,000 tests per one million 
inhabitants was comprised, for the most part, of 
countries in Western Europe, countries in Asia with 
high gross domestic product (GDP) per capita, Canada, 
the United States and Chile. The United Arab Emirates 
and Bahrain stood out in this group, for presenting 
test coefficients much higher than the others, above 
Figure 1 – Number of SARS-CoV-2 diagnostic tests per one million inhab. in the 50 countries with the highest COVID-19 case 
numbers, as at August 19, 2020
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550,000 tests per one million inhabitants. Sweden, 
France, Holland, Turkey, Romania, Poland, Brazil, 
Peru, Panama, China, Oman and South Africa were 
distributed in an intermediate block, between 100 
and 50,000 tests per one million inhabitants. Those 
with the lowest number of tests performed, i.e., less 
than 50,000 tests per one million inhabitants, are 
the majority of Latin American countries, Asian 
countries with lower GDP per capita and Japan, 
besides Nigeria and Egypt.
Figure 2A shows that cumulative incidence 
increased with the number of tests performed per one 
million inhabitants. (ρxy = 0.558), while Figure 2B 
shows the low correlation between mortality and the 
number of tests performed per one million inhabitants. 
(ρxy = 0.253). Most Latin American countries had 
higher than expected cumulative incidence and 
mortality rates, according to their testing rates. As 
for the European countries studied, their cumulative 
incidence rates were close to expected for countries 
with the corresponding testing rate; their mortality 
rate, however, was higher than expected, in general. 
Most Asian countries that were evaluated, constituting 
the group with the highest levels of COVID-19 testing, 
had cumulative incidence rates close to expected, but 
mortality rates lower than that of other nations with 
the same test rates.
Figure 2C shows that there was no correlation 
between the fatality rate and testing per one million 
inhab. (ρxy = -0.057). European countries such 
as France, Italy, Belgium, Netherlands and United 
Kingdom, and Mexico, in North America, stood out 
for having much higher-than-expected fatality rates, 
according to their testing rates.
Lastly, in Figure 2D, it is possible to observe the 
decrease in the proportion of positive tests as the 
number of tests performed increased (ρxy = -0.626). 
Countries like Egypt, Bolivia and Mexico presented 
a high proportion of positive tests. In Brazil, the 
proportion was 24.5% for the period studied.
Discussion
The results of this study indicate that the testing 
rate varied immensely among the 50 countries with 
the highest number of diagnosed cases. There were 
countries that performed more than 550,000 tests 
per one million inhabitants, such as the United Arab 
Emirates and Bahrain, and others that performed less 
than 1,350 tests per one million inhabitants, such as 
Egypt. The findings show that some epidemiological 
indicators, such as cumulative incidence and positive 
test proportion, are correlated to the number of tests 
performed for diagnosis of infection, whereas the 
mortality and fatality rates showed low correlation 
with this indicator.
Some countries, among the 50 observed, reported 
low population testing rates. These are low and 
middle-income countries, located in Latin America, 
Asia and Africa, where the epidemic started more 
recently, when compared to European countries. 
The exception was Japan. The low number of tests 
performed per one million inhabitants in these 
countries may be related to resource prioritization, 
directed only towards severe cases, as occurs in 
Mexico,10 or to difficulty in expanding testing 
capacity, as occurs in Egypt11 and Nigeria.12 
On the other hand, countries that have already 
performed a number of tests corresponding to more 
than half their population, such as the United Arab 
Emirates and Bahrain, stand out. It is possible that 
previous experiences of these countries with the Middle 
East Respiratory Syndrome (MERS) left them better 
prepared to accommodate the demands generated 
by subsequent outbreaks of respiratory viruses such 
as SARS-CoV-2.13 However, the high testing rate did 
not prevent these countries from being among the 
50 with the highest number of cases. This is possibly 
due to the lack of coupling extensive testing with 
non-pharmacological control measures, although 
the recent drop in the number of daily cases in these 
countries1 may indicate that the more comprehensive 
testing employed contributes to the decline observed.
The data analyzed showed a moderate correlation 
between the testing rate and cumulative incidence. 
It is expected that as more tests are performed, more 
cases will be diagnosed. China seems to emerge as an 
exception to this pattern: despite having expanded 
its testing strategy, allowing RT-PCR to be performed 
even for people with low suspicion of COVID-19, 
an expressive low cumulative incidence rate was 
maintained, compared to other countries with the 
same testing rate. This behavior can be explained 
by the combination of the growing number of 
diagnostic tests performed and isolation of new cases.14 
This type of behavior has also been noticed in 
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countries that have been successful in combating the 
epidemic, despite not being among the 50 with the 
highest number of cases, such as New Zealand,15 South 
Korea6 and Iceland.16 In the case of China, previous 
experiences with MERS and severe acute respiratory 
syndrome (SARS) may also have contributed to it 
having a pattern different from the others.14 Moreover, 
it is important to consider that in February 2020, 
when China was reaching the highest number of 
daily cases to date, the diagnostic tests developed were 
submitted to emergency approval procedures. This 
may have impacted on a considerable percentage of 
false negative results, which may also explain, albeit 
partially, China’s lower cumulative incidence.14,17
The mortality rate was positively correlated with 
testing, as was cumulative incidence, although with 
less magnitude. Some European countries, where 
cumulative incidence was within expectations, 
presented COVID-19 mortality rates above those of 
countries with equivalent test rates. Several factors 
could contribute to this result, such as older age 
of the population and therefore the presence of 
comorbidities.18,19 Higher mortality in Western European 
countries may also be related to better investigation of 
deaths than of cases.20 Moreover, a change in the criteria 
for defining death or the difficulty in attesting to death 
from COVID-19 can interfere with these estimates. An 
example of this possibility lies in Italy, where researchers 
have reported difficulty in differentiating deaths 
directly caused by SARS-CoV-2 from deaths due to other 
causes, in individuals only infected with the virus. 
This fact is attributed to the presence of significant 
comorbidities in the vast majority of those diagnosed 
with COVID-19 who died: 98.8% had at least one 
comorbidity; and 48.6%, three or more.21
However, when comparing mortality rates, other 
factors must be considered, such as the moment in the 
epidemic. It can be noticed that countries with wider 
testing, such as China and Singapore, have mortality 
rates comparable to those of Nigeria, which came in 
second place among countries that tested less among 
the 50 with the highest number of cases assessed in this 
study. A low mortality rate does not necessarily reflect 
success in controlling the pandemic.22
Case fatality rate had low correlation with testing. If 
both cases (including asymptomatic cases) and deaths 
were adequately identified, COVID-19 fatality would be 
expected to be close to 1%;23 with few exceptions, the vast 
majority of countries reported a rate above this value. 
In some European countries such as France, Italy, the 
United Kingdom, Belgium and the Netherlands, as well 
as Mexico, this indicator is above 10%.
Fatality is influenced by demographic structure 
(countries with a higher proportion of elderly tend 
to present higher case fatality rate) and by national 
health system organization. A Public Health system 
that is better prepared to identify and isolate cases 
and treat those in need, will account for lower case 
fatality rate. Also, countries that identify deaths better 
than cases tend to present higher case fatality rate.20 In 
relation to this indicator, Brazil is close to the expected 
given its testing rate. In view of the country’s current 
scenario, it is possible to assume that the Brazilian 
result comes from widespread underreporting of both 
deaths and cases of SARS-CoV-2 infection.
Regarding the positive result test proportion, it 
was found that the higher the test rate, the lower this 
proportion. Some countries, such as Egypt, Mexico 
and Bolivia, showed a high positive test proportion, 
above 40%, indicating that only the most severe 
patients are tested, namely those seeking outpatient 
or hospital medical assistance. In addition, a high 
positive test proportion indicates that a country is 
not able to measure the actual extent of virus spread 
in its territory.24 
The The World Health Organization (WHO) 
recommends: for a country to start relaxing 
quarantine and social distancing, the positive test rate 
should be 5% at the most for no less than 14 days.24 
Latin American countries seem far from meeting this 
goal, since all of them have a positive test proportion 
of around 20% or more. Examples of this are Mexico 
and Brazil, which face similar problems, starting 
from the federal government’s refusal to recognize the 
pandemic as a Public Health problem, and therefore 
not tackling it through health policies, coordinated 
across ministries, jointly with their federative units.25,26 
Both countries test only serious cases, despite Brazil’s 
slowly increasing testing rate: 64,593 tests per one 
million inhabitants when this report was concluded. 
Mexico (9,281 tests per one million inhabitants) 
continues to be one of the countries that least tests 
among the 50 with the highest number of diagnosed 
cases.22 Even in a testing scenario that falls short of 
what is necessary, and where there is a high percentage 
of positive tests - Mexico (43.9%) and Brazil (24.5%) 
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- both countries have adopted measures to gradually 
reopen the economy that are not supported by 
epidemiological data or WHO recommendations.24 
This deficient testing, verified in other Latin American 
nations as well, combined with prioritizing laboratory 
diagnosis for the severely symptomatic, may explain 
the higher than expected cumulative incidence and 
mortality rates when compared to other countries with 
a similar testing rate.
A low testing rate is one of the factors that can result 
in an underestimated number of infected people and 
therefore lower quality health indicators.2,7 Studies 
have shown that the mortality rate would be a more 
reliable indicator compared to incidence and case 
fatality,7,27 since the number of SARS-CoV-2 infection 
cases are generally more underestimated than the 
number of deaths from COVID-19.20
Adequate testing, which includes mild 
symptomatic and asymptomatic individuals, is 
crucial for the accurate and valid assessment of 
health indicators. A prediction study on data from 
42 countries published in early April 2020 showed 
that a 10% increase in SARS-CoV-2 testing would lead 
to an increase of approximately 9% in the number 
of new cases, and a 9% reduction in case fatality 
rate.28 Using graph analysis, another study found 
that the testing strategy conducted in Italy identified 
a significant portion of the difference between case 
fatality rate in that country and others, such as 
China.29 The supposed shift from a narrower testing 
policy (which favors people with severe symptoms, 
prior contact with a confirmed case, belonging to a 
‘high-risk’ group; or the combination of these and 
other criteria)6 to one with broader criteria and mass 
population testing, would result in greater detection 
of SARS-CoV-2 infected people, directly impacting 
better quality of health indicators. This change, 
moreover, would culminate in higher COVID-19 
incidence and mortality.
The important role played by epidemiological 
surveillance in relation to the quality of COVID-19 
indicators is worth stressing, as it is essential to obtain 
accurate information and draw a real picture of the 
health problem, as well as actions and interventions 
needed to address and solve it. Epidemiological 
surveillance is especially capable of assisting in 
COVID-19 case identification, through surveillance of 
the contacts of diagnosed and suspected cases, active 
surveillance at the Primary Care level of the Brazilian 
National Health System (SUS) and awareness as to the 
importance of prompt and correct case notification 
by professionals engaged in fighting the pandemic. As 
such, the quality of health indicators is also influenced 
- strongly - by epidemiological surveillance actions, 
essential for Public Health.30
Although this study presents important 
considerations on the impact of laboratory testing on 
the COVID-19 pandemic follow-up indicators, it has 
some limitations. The first is the quality of the available 
data, which do not distinguish the type of test performed 
(RT-PCR or serologic test). Some countries administer 
both tests for different purposes: whereas RT-PCR 
is employed to diagnose active infections, serologic 
tests are used to monitor past infections. However, it 
is not possible to guarantee whether these tests have 
been used adequately. The study’s second limitation is 
the difficulty in comparing data from countries that 
adopt different testing strategies, with greater or lesser 
involvement of serologic tests in the total of confirmed 
cases. Since SARS-CoV-2 is an emerging infectious 
agent and the available assays are not yet fully accurate 
for diagnosing infection, the consistency of laboratory 
results can be poor, which limits the conclusions than 
can be drawn. A third limitation of the study is that even 
very broad testing strategies, such as those adopted in 
some Asian countries, do not test the entire population. 
Given that a significant proportion of those infected 
develop subclinical infection, all indicators presented 
may be underestimated (cumulative incidence) or 
overestimated (mortality and case fatality rates). As 
the fourth and last limitation to consider, it must be 
taken into account that cases do not reflect solely those 
diagnosed by laboratory tests. Some countries have 
adopted clinical-epidemiological criteria in their case 
definition, which can further obscure the results found.
Despite the heterogeneity identified in the 
population testing rate and inconsistencies in the 
data, the survey results indicate that the vast majority 
of countries do not test sufficiently to ensure the 
quality of health indicators relative to COVID-19 
and enable the planning of a safe return to normal 
social life throughout and after the pandemic. Low 
testing rates can result in underestimating the 
number of SARS-CoV-2 infected individuals and 
COVID-19 deaths. Health care managers need to 
be aware of how infection testing and surveillance 
Effect of testing on COVID-19 monitoring indicators
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are reflected in the quality of health indicators 
and their impact on health action planning. It is 
therefore necessary to provide more testing for 
the population in order to adequately monitor 
the epidemic’s extent. Only through reliable data 
will economic reopening policies be responsibly 
and safely planned for society, thus reducing the 
odds of new virus transmission waves and spread 
of the disease.
The conclusion is that the availability of more tests 
for the population is, on its own, insufficient to improve 
the quality of health indicators. This strategy must 
be supported by other measures, such as isolation of 
diagnosed cases and tracing their respective contacts. 
To achieve this, it is important that SUS Primary Care 
and Health Surveillance be well structured. Countries 
such as Brazil, served by a highly capillary health 
system, can make use of existing network and its 
Family Health Strategy, for following-up on COVID-19 
cases and mapping their recent contacts.
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